Retatrutide is being called the next-generation GLP-1 weight loss drug — but how does it compare to Semaglutide (Ozempic/Wegovy) and Tirzepatide (Mounjaro/Zepbound)? In this video, Dr. Alex Tatem breaks down everything you need to know: what GLP-1 agonists are, how Retatrutide works as the first triple agonist (GLP-1, GIP, glucagon), its clinical trial results, potential side effects, and when it might hit the market. We also cover Semaglutide vs Tirzepatide vs Retatrutide head-to-head, fat loss outcomes, safety considerations, and the future of obesity treatment. If you want clear science on the most powerful GLP-1 yet, you’re in the right place. Timecode 2:12 - What GLP-1 agonists are and how they work 4:24 - What makes Retatrutide different from semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) 7:51 - How Retatrutide compares in clinical trials for weight loss, blood sugar, and fat burn 10:16 - Side effects and safety profile you NEED to know 12:45 - When Retatrutide could realistically hit the market (hint: Phase 3 is still running) ⚠️ Disclaimer: This video is for educational purposes only. It is not medical advice. Always talk to your doctor before making health decisions. Retatrutide is showing up to 24% total weight loss in Phase 2 studies, potentially outperforming both semaglutide and tirzepatide. But it’s still experimental, not FDA-approved, and anything online labeled as “Retatrutide” is unregulated. 💬 Drop a comment with what you think: is Retatrutide the real deal or just hype? 📲 Join our Discord (link in bio) where we’re discussing peptides, bloodwork, and men’s health with a like-minded community. 👍 Smash the like button, subscribe, and hit the bell—we drop new videos every week. That’s Retatrutide. Triple agonist. Triple threat. The future of fat loss? Proceed accordingly.